Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Piramal Enterprises Limited clinical trials
Also known as Nicholas Piramal.
The registry lists 23 studies whose lead sponsor is Piramal Enterprises Limited. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 26, 2014.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Piramal Enterprises Limited.
- Piramal Enterprises Limited23 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 23 of 23.
- Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese SubjectsCompletedNCT01910571Phase 1
- Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid TumorsSuspendedNCT01762410Phase 1
- Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid TumorsSuspendedNCT01779336Phase 1
- A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00CompletedNCT01903018Phase 2
- Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF MutationSuspendedNCT01841463Phase 1
- A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and CarboplatinTerminatedNCT01333137Phase 1
- Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)SuspendedNCT02117336Phase 1
- Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187Status unknownNCT01874366Phase 1
- A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 DiabetesTerminatedNCT01674348Phase 2
- A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck CancerCompletedNCT00824343Phase 2
- Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese SubjectsTerminatedNCT01764425Phase 1
- Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 ExpressionCompletedNCT00835419Phase 2
- A Multicenter Phase I Clinical Study of a New Compound P1446A-05 in Patients With Advanced Refractory MalignanciesCompletedNCT00772876Phase 1
- A Phase IV Clinical Trial to Study the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque PsoriasisCompletedNCT01373567Phase 4
- Study of P3914 to Evaluate the Safety, Tolerability, Food Effect & Pharmacokinetics in Healthy Male Subjects and Efficacy & Safety of P3914 in Patients With Acute Dental PainTerminatedNCT01339156Phase 1
- Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck CancerCompletedNCT00899054Phase 1/2
- Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple MyelomaCompletedNCT00882063Phase 1/2
- A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory MalignanciesCompletedNCT00840190Phase 1
- A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell LymphomaTerminatedNCT00843050Phase 2
- Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic CancerCompletedNCT00898287Phase 1/2
- Phase I Study for Safety and Efficacy of P276-00 in Subjects With MyelomaWithdrawnNCT00547404Phase 1
- Phase I Study of P276-00 in Patients With Advanced Refractory NeoplasmsTerminatedNCT00408018Phase 1
- Open Label Phase I Study of P276-00 in Patients With Advanced Refractory NeoplasmsCompletedNCT00407498Phase 1